Kevin L. Weiss

Kevin L. Weiss

Auto-generated profile, based on publicly available information

Kevin L. Weiss

Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DKDaniel W. Kneller
Daniel W. Kneller
GPGwyndalyn Phillips
Gwyndalyn Phillips
KWKevin L. Weiss
Kevin L. Weiss
SPSwati Pant
Swati Pant
QZQiu Zhang
Qiu Zhang
AKAndrey Kovalevsky
Andrey Kovalevsky
The main protease (3CL Mpro) from SARS–CoV-2, the etiological agent of COVID-19, is an essential enzyme for viral replication. 3CL Mpro possesses an unusual catalytic dyad composed of Cys145 and His41 residues. A critical question in the field has been what the protonation states of the ionizable residues in the substrate-binding active-site cavity are; resolving this point would help understand the catalytic details of the enzyme and inform rational drug development against this pernicious virus. Here, we present the room-temperature neutron structure of 3CL Mpro, which allowed direct determination of hydrogen atom positions and, hence, protonation states in the protease. We observe that the catalytic site natively adopts a zwitterionic reactive form in which Cys145 is in the negatively charged thiolate state and His41 is doubly protonated and positively charged, instead of the neutral unreactive state usually envisaged. The neutron structure also identified the protonation states, and thus electrical charges, of all other amino acid residues and revealed intricate hydrogen-bonding networks in the active-site cavity and at the dimer interface. The fine atomic details present in this structure were made possible by the unique scattering properties of the neutron, which is an ideal probe for locating hydrogen positions and experimentally determining protonation states at near-physiological temperature. Our observations provide critical information for structure-assisted and computational drug design, allowing precise tailoring of inhibitors to the enzyme's electrostatic environment.

27 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDaniel W. Kneller
Daniel W. Kneller
HLHui Li
Hui Li
GPGwyndalyn Phillips
Gwyndalyn Phillips
KWKevin L. Weiss
Kevin L. Weiss
QZQiu Zhang
Qiu Zhang
AKAndrey Kovalevsky
Andrey Kovalevsky
Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (Mpro) is critical for virus replication and thus is considered an attractive drug target. We performed the design and characterization of three covalent hybrid inhibitors BBH-1, BBH-2 and NBH-2 created by splicing components of hepatitis C protease inhibitors boceprevir and narlaprevir, and known SARS-CoV-1 protease inhibitors. A joint X-ray/neutron structure of the Mpro/BBH-1 complex demonstrates that a Cys145 thiolate reaction with the inhibitor’s keto-warhead creates a negatively charged oxyanion. Protonation states of the ionizable residues in the Mpro active site adapt to the inhibitor, which appears to be an intrinsic property of Mpro. Structural comparisons of the hybrid inhibitors with PF-07321332 reveal unconventional F···O interactions of PF-07321332 with Mpro which may explain its more favorable enthalpy of binding. BBH-1, BBH-2 and NBH-2 exhibit comparable antiviral properties in vitro relative to PF-07321332, making them good candidates for further design of improved antivirals.

25 June 2014 in Journal of Applied Crystallography
Verified
Journal Article
Closed access
William T. HellerWilliam T. Heller
William T. Heller
VUVolker Urban
Volker Urban
GLGary W. Lynn
Gary W. Lynn
KWKevin L. Weiss
Kevin L. Weiss
HOHugh M. O'Neill
Hugh M. O'Neill
DMDean A. Myles
Dean A. Myles

28 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BSBrian C. Sanders
Brian C. Sanders
SPSuman Pokhrel
Suman Pokhrel
ALAudrey D. Labbe
Audrey D. Labbe
IMIrimpan I. Mathews
Irimpan I. Mathews
CCConnor J. Cooper
Connor J. Cooper
JPJerry M. Parks
Jerry M. Parks
Direct-acting antivirals are needed to combat coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The papain-like protease (PLpro) domain of Nsp3 from SARS-CoV-2 is essential for viral replication. In addition, PLpro dysregulates the host immune response by cleaving ubiquitin and interferon-stimulated gene 15 protein from host proteins. As a result, PLpro is a promising target for inhibition by small-molecule therapeutics. Here we design a series of covalent inhibitors by introducing a peptidomimetic linker and reactive electrophile onto analogs of the noncovalent PLpro inhibitor GRL0617. The most potent compound inhibits PLpro with kinact/KI = 9,600 M−1 s−1, achieves sub-μM EC50 values against three SARS-CoV-2 variants in mammalian cell lines, and does not inhibit a panel of human deubiquitinases (DUBs) at >30 μM concentrations of inhibitor. An X-ray co-crystal structure of the compound bound to PLpro validates our design strategy and establishes the molecular basis for covalent inhibition and selectivity against structurally similar human DUBs. These findings present an opportunity for further development of covalent PLpro inhibitors.

1 December 2018 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Closed access
PDF file
RARana Ashkar
Rana Ashkar
HBHassina Bilheux
Hassina Bilheux
Heloisa BordalloHeloisa Bordallo
Heloisa Bordallo
RBRobert M. Briber
Robert M. Briber
DCDavid J. E. Callaway
David J. E. Callaway
JSJeremy Smith
Jeremy Smith

16 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SDSteven Dajnowicz
Steven Dajnowicz
RJRyne C. Johnston
Ryne C. Johnston
JPJerry M. Parks
Jerry M. Parks
MBMatthew P. Blakeley
Matthew P. Blakeley
DKDavid A. Keen
David A. Keen
TMTimothy C. Mueser
Timothy C. Mueser
Enzymes dependent on pyridoxal 5′-phosphate (PLP, the active form of vitamin B6) perform a myriad of diverse chemical transformations. They promote various reactions by modulating the electronic states of PLP through weak interactions in the active site. Neutron crystallography has the unique ability of visualizing the nuclear positions of hydrogen atoms in macromolecules. Here we present a room-temperature neutron structure of a homodimeric PLP-dependent enzyme, aspartate aminotransferase, which was reacted in situ with α-methylaspartate. In one monomer, the PLP remained as an internal aldimine with a deprotonated Schiff base. In the second monomer, the external aldimine formed with the substrate analog. We observe a deuterium equidistant between the Schiff base and the C-terminal carboxylate of the substrate, a position indicative of a low-barrier hydrogen bond. Quantum chemical calculations and a low-pH room-temperature X-ray structure provide insight into the physical phenomena that control the electronic modulation in aspartate aminotransferase.